TEST:

NeoTYPE® Lung Tumor Profile

"NeoGenomics, Inc...announced today that they are partnering with Eli Lilly and Company on a sponsored testing program for eligible patients with metastatic non-small cell lung cancer (NSCLC) at no cost...The Lilly Lung Cancer Sponsored Testing Program will utilize the NeoTYPE® DNA and RNA Assay to provide eligible metastatic NSCLC patients with enhanced access to a targeted genomic test offering that can help physicians and patients make informed treatment decisions. For cases where results are not attainable due to low tissue input or when an invasive biopsy is medically contraindicated, eligible patients are able to instead use InVisionFirst®-Lung Liquid Biopsy at no cost."

This tumor was Thyroid Transcription Factor-1 negative, which statistically has a poorer prognosis due to its invasive nature compared to its counterpart. Fortunately, based on her PET scan, there is no evidence of metastatic disease and she is planned for a lobectomy.(Figure 1)